|
KMID : 0869620140310061110
|
|
Journal of Korean Society of Hospital Pharmacists
2014 Volume.31 No. 6 p.1110 ~ p.1118
|
|
|
Efficacy of Rasburicase on Hyperuricemia in Adult Patients with Malignant Tumor
|
|
Cheong Jee-Woon
Kim Young-Ae
Cho Eun-Jeong
Lee Yong-Hwa
Lee Hye-Sook
Kim Hyang-Suk
|
|
|
Abstract
|
|
|
|
Rasburicase reduces uric acid levels by converting uric acid to allantoin. Allopurinol is the most used in TLS(tumor lysis syndrome). However, it has limitations such as slow onset and kidney toxicity. In Korea, a few research studies on rasburicase have been performed on pediatric patients under 18 years. However, efficacy study of rasburicase in adult patients is limited. In this study, we determined the efficacy of rasburicase on hyperuricemia in adult patients with malignant tumor and analyzed the factors that might have affected its ability to convert uric acid. From November 2006 to July 2012, a retrospective study was designed to analyze laboratory changes of patients administrated 0.2 mg/kg rasburicase in Seoul National University Hospital who had malignant tumor over the age of 18. A total of 21 patients was included. This study observed uric acid, creatinine, blood urea nitrogen etc. until 96 hours after the first administration of raAfter 12 hours, uric acid levels of all patients were significantly (p<0.05) decreased. Average uric acid levels were decreased from 10.69±4.07 mg/dL to 1.94±3.13 mg/dL and maintained until 96 hours post the first administration of rasburicase. Regression analysis revealed that lower percentage of reduced degree of 96 hours-uric acid was associated with higher numbers of white blood cells (WBC) and higher plasma uric acid levels before administration. In conclusion, rasburicase reduced uric acid levels in Korean adult patients effectively. Therefore, a careful monitoring will be required for patients who have high white blood cells or uric acid levels because higher WBC and higher plasma uric acid levels before administration was associated with lower reduction of uric acid.sburicase.
|
|
|
KEYWORD
|
|
|
Rasburicase, Tumor Lysis Syndrome, Hyperuricemia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|